ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 166 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2019. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $80,000 | +166.7% | 1,348 | +68.1% | 0.00% | – |
Q3 2019 | $30,000 | -21.1% | 802 | -3.0% | 0.00% | – |
Q2 2019 | $38,000 | +15.2% | 827 | 0.0% | 0.00% | – |
Q1 2019 | $33,000 | -31.2% | 827 | -21.0% | 0.00% | – |
Q4 2018 | $48,000 | +336.4% | 1,047 | +349.4% | 0.00% | – |
Q3 2018 | $11,000 | -85.1% | 233 | -77.0% | 0.00% | -100.0% |
Q2 2018 | $74,000 | 0.0% | 1,015 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $74,000 | -26.7% | 1,015 | -33.4% | 0.00% | 0.0% |
Q4 2017 | $101,000 | +27.8% | 1,524 | -2.6% | 0.00% | 0.0% |
Q3 2017 | $79,000 | +61.2% | 1,564 | +49.0% | 0.00% | 0.0% |
Q2 2017 | $49,000 | +58.1% | 1,050 | +18.5% | 0.00% | – |
Q1 2017 | $31,000 | +181.8% | 886 | -1.6% | 0.00% | – |
Q4 2016 | $11,000 | -8.3% | 900 | 0.0% | 0.00% | – |
Q3 2016 | $12,000 | +33.3% | 900 | 0.0% | 0.00% | – |
Q2 2016 | $9,000 | -40.0% | 900 | 0.0% | 0.00% | – |
Q1 2016 | $15,000 | -25.0% | 900 | 0.0% | 0.00% | – |
Q4 2015 | $20,000 | – | 900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |